| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. [PubChem] |
| Indication |
For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma |
| Pharmacology |
Methazolamide is topical carbonic anhydrase inhibitor. Methazolamide is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers. Methazolamide is a sulfonamide derivative; however, it does not have any clinically significant antimicrobial properties. Although methazolamide achieves a high concentration in the cerebrospinal fluid, it is not-considered an effective anticonvulsant. Methazolamide has a weak and transient diuretic effect, therefore use results in an increase in urinary volume, with excretion of sodium, potassium and chloride. |
| Toxicity |
Electrolyte imbalance, development of an acidotic state, and central nervous system effects might be expected to occur in the case of an overdose. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
Methazolamide is well absorbed from the gastrointestinal tract. |
| Half Life |
14 hours |
| Protein Binding |
55% |
| Distribution |
* 17 to 23 L |
| References |
| • |
Iyer GR, Bellantone RA, Taft DR: In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics. J Pharmacokinet Biopharm. 1999 Feb;27(1):45-66.
[Pubmed]
|
| • |
Shirato S, Kagaya F, Suzuki Y, Joukou S: Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol. 1997 Apr;115(4):550-3.
[Pubmed]
|
| • |
Skorobohach BJ, Ward DA, Hendrix DV: Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res. 2003 Feb;64(2):183-7.
[Pubmed]
|
|
| External Links |
|